Active Not RecruitingNCT06506019
Neurobiological Effects of Psilocybin in Treatment Resistant Depression in bipolarity
Medication studyAges 18–65Canada
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 9, 2024
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 30
- Sponsor
- University Health Network, Toronto
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Device, Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06506019
- Official title
Show the full official title
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Health Network, Toronto, a university.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
